Abbott India jumped 6.17% to Rs 27,756.50 after the company's net profit increased 16.01% to Rs 360.78 crore in Q3 FY25 as against Rs 310.98 crore posted in Q3 FY24.
Revenue from operations grew by 12.32% to Rs 1,614.28 crore in the quarter ended 31 December 2024.Profit before tax stood at Rs 487.59 crore in the third quarter of FY25, up 15.49% from Rs 422.16 crore posted in the same period a year ago.
On nine-month basis, the pharma companys net profit grew 14.57% to Rs 1,047.40 crore on 8.94% rise in revenue from operations to Rs 4,804.56 crore in 9M FY24 over 9M FY23.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app